SECAUCUS, N.J., April 19, 2018 /PRNewswire/ -- Quest
Diagnostics Incorporated (NYSE: DGX), the world's leading provider
of diagnostic information services, announced today financial
results for the first quarter ended March
31, 2018.
"We delivered strong revenue and earnings growth in the first
quarter," said Steve Rusckowski,
Chairman, President and CEO. "We grew revenue 3.7 percent
despite severe winter weather and the impact of lower Medicare
reimbursement under PAMA. Earnings growth was driven by our
continued strong execution as well as the benefits of tax
reform. Our two-point strategy of accelerating growth and
driving operational excellence continues to produce
results."
|
Three Months Ended
March 31,
|
|
2018
|
|
2017
|
|
Change
|
|
(dollars in millions,
except per share data)
|
Reported:
|
|
|
|
|
|
Net revenues
(a)
|
$
|
1,884
|
|
|
$
|
1,817
|
|
|
3.7
|
%
|
Diagnostic
Information Services revenues (a)
|
$
|
1,803
|
|
|
$
|
1,730
|
|
|
4.1
|
%
|
Revenue per
requisition
|
|
|
|
|
1.6
|
%
|
Requisition
volume
|
|
|
|
|
2.2
|
%
|
Operating income (a)
(b)
|
$
|
272
|
|
|
$
|
279
|
|
|
(2.5)
|
%
|
Operating income as a
percentage of net revenues (a) (b)
|
14.5
|
%
|
|
15.4
|
%
|
|
(90)
|
bps
|
Net income
attributable to Quest Diagnostics (b)
|
$
|
177
|
|
|
$
|
164
|
|
|
8.2
|
%
|
Diluted EPS
(b)
|
$
|
1.27
|
|
|
$
|
1.16
|
|
|
9.5
|
%
|
Cash provided by
operations
|
$
|
180
|
|
|
$
|
196
|
|
|
(8.5)
|
%
|
Capital
expenditures
|
$
|
73
|
|
|
$
|
42
|
|
|
75.4
|
%
|
|
|
|
|
|
|
Adjusted:
|
|
|
|
|
|
Operating income
(a)
|
$
|
303
|
|
|
$
|
297
|
|
|
1.9
|
%
|
Operating income as a
percentage of net revenues (a)
|
16.1
|
%
|
|
16.3
|
%
|
|
(20)
|
bps
|
Net income
attributable to Quest Diagnostics
|
$
|
192
|
|
|
$
|
159
|
|
|
20.8
|
%
|
Diluted EPS excluding
amortization
|
$
|
1.52
|
|
|
$
|
1.22
|
|
|
24.6
|
%
|
|
(a) Net revenues and selling,
general and administrative expenses for the three months ended
March 31, 2017 have been
restated to
reflect the impact of new revenue recognition rules that are
effective January 1, 2018 and were adopted on
a retrospective
basis. Under the new rules, the Company reports uncollectible
balances associated with patient
responsibility as
a reduction in net revenues when historically these amounts were
classified as bad debt expense
within selling,
general and administrative expenses.
|
|
(b) For further details
impacting the year-over-year comparisons related to operating
income, operating income as a
percentage of net
revenues, net income attributable to Quest Diagnostics, and diluted
EPS, see note 2 of the financial
tables attached
below.
|
Outlook for Full Year 2018
The company's outlook for full year 2018 remains unchanged as
follows:
|
Current
Outlook
|
|
Low
|
|
High
|
Revenues
(a)
|
$7.70
billion
|
|
$7.77
billion
|
Revenue increase
(a)
|
4%
|
|
5%
|
Reported diluted
EPS
|
$5.42
|
|
$5.62
|
Adjusted diluted EPS
excluding amortization
|
$6.50
|
|
$6.70
|
Cash provided by
operations
|
Approximately $1.3
billion
|
Capital
expenditures
|
$350
million
|
|
$400
million
|
|
(a) The outlook for 4% to 5%
revenue growth in 2018 represents management's estimates for 2018
versus 2017
reported
revenues adjusted to reflect the impact of new revenue recognition
rules that are effective January
1, 2018.
Full year 2017 revenues adjusted to reflect the new rules were
$7,402 million. See note 5 of the
financial
tables attached below.
|
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to
measures under the accounting principles generally accepted in
the United States ("GAAP").
The term "adjusted" refers to non-GAAP measures as follows:
(i) for the purpose of income measures the term "adjusted" refers
to operating performance measures that exclude special items such
as restructuring and integration charges, excess tax benefit
("ETB") associated with stock based compensation and other items;
and (ii) the term "adjusted diluted EPS excluding amortization"
represents the company's diluted EPS before the impact of special
items (described above) and amortization expense.
Non-GAAP adjusted measures are presented because management
believes those measures are useful adjuncts to GAAP results.
Non-GAAP adjusted measures should not be considered as an
alternative to the corresponding measures determined under
GAAP. Management may use these non-GAAP measures to evaluate
our performance period over period and relative to competitors, to
analyze the underlying trends in our business, to establish
operational budgets and forecasts and for incentive compensation
purposes. We believe that these non-GAAP measures are useful
to investors and analysts to evaluate our performance period over
period and relative to competitors, as well as to analyze the
underlying trends in our business and to assess our
performance. The additional tables attached below include
reconciliations of adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to
discuss financial results beginning at 8:30
a.m. Eastern Time today. The conference call can be
accessed in listen-only mode by dialing 773-756-0467, passcode
3214469. The company suggests participants dial in
approximately 10 minutes before the call.
A replay of the call may be accessed online at
www.QuestDiagnostics.com/investor or by phone at 800-846-1910 for
domestic callers or 402-280-9953 for international callers.
Telephone replays will be available from approximately 10:30 a.m. Eastern Time on April 19, 2018 until midnight Eastern Time on May 3, 2018. Anyone listening to the call
is encouraged to read the company's periodic reports, on file with
the Securities and Exchange Commission, including the discussion of
risk factors and historical results of operations and financial
condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve
health outcomes. Derived from the world's largest database of
clinical lab results, our diagnostic insights reveal new avenues to
identify and treat disease, inspire healthy behaviors and improve
health care management. Quest annually serves one in three
adult Americans and half the physicians and hospitals in
the United States, and our 45,000
employees understand that, in the right hands and with the right
context, our diagnostic insights can inspire actions that transform
lives. www.QuestDiagnostics.com.
The statements in this press release which are not historical
facts may be forward-looking statements. Readers are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date that they are made and
which reflect management's current estimates, projections,
expectations or beliefs and which involve risks and uncertainties
that could cause actual results and outcomes to be materially
different. Risks and uncertainties that may affect the future
results of the company include, but are not limited to, adverse
results from pending or future government investigations, lawsuits
or private actions, the competitive environment, changes in
government regulations, changing relationships with customers,
payers, suppliers or strategic partners and other factors discussed
in the company's most recently filed Annual Report on Form 10-K and
in any of the company's subsequently filed Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K, including those
discussed in the "Business," "Risk Factors," "Cautionary Factors
that May Affect Future Results" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of those reports.
This earnings release, including the attached financial tables,
is available online in the Newsroom section at
www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics
Incorporated and Subsidiaries
|
Consolidated
Statements of Operations
|
For the Three
Months Ended March 31, 2018 and 2017
|
(in millions,
except per share data)
|
(unaudited)
|
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
Net
revenues
|
$
|
1,884
|
|
|
$
|
1,817
|
|
|
|
|
|
Operating costs
and expenses and other operating income:
|
|
|
|
Cost of
services
|
1,226
|
|
|
1,165
|
|
Selling, general and
administrative
|
363
|
|
|
355
|
|
Amortization of
intangible assets
|
22
|
|
|
17
|
|
Other operating
expense, net
|
1
|
|
|
1
|
|
Total operating costs
and expenses, net
|
1,612
|
|
|
1,538
|
|
|
|
|
|
Operating
income
|
272
|
|
|
279
|
|
|
|
|
|
Other income
(expense):
|
|
|
|
Interest expense,
net
|
(41)
|
|
|
(36)
|
|
Other (expense)
income, net
|
(2)
|
|
|
3
|
|
Total non-operating
expenses, net
|
(43)
|
|
|
(33)
|
|
|
|
|
|
Income before
income taxes and equity in earnings of equity method
investees
|
229
|
|
|
246
|
|
Income tax
expense
|
(52)
|
|
|
(78)
|
|
Equity in earnings
of equity method investees, net of taxes
|
12
|
|
|
7
|
|
Net
income
|
189
|
|
|
175
|
|
Less: Net income
attributable to noncontrolling interests
|
12
|
|
|
11
|
|
Net income
attributable to Quest Diagnostics
|
$
|
177
|
|
|
$
|
164
|
|
|
|
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common
stockholders:
|
|
|
|
Basic
|
$
|
1.30
|
|
|
$
|
1.19
|
|
|
|
|
|
Diluted
|
$
|
1.27
|
|
|
$
|
1.16
|
|
|
|
|
|
|
|
|
|
Weighted average
common shares outstanding:
|
|
|
|
Basic
|
136
|
|
|
137
|
|
Diluted
|
139
|
|
|
141
|
|
|
|
|
|
Quest Diagnostics
Incorporated and Subsidiaries
|
Consolidated
Balance Sheets
|
March 31,
2018 and December 31, 2017
|
(in millions,
except per share data)
|
(unaudited)
|
|
|
March 31,
2018
|
|
December 31,
2017
|
Assets
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
|
124
|
|
|
$
|
137
|
|
Accounts receivable,
net
|
1,026
|
|
|
924
|
|
Inventories
|
94
|
|
|
95
|
|
Prepaid expenses and
other current assets
|
127
|
|
|
150
|
|
Total current
assets
|
1,371
|
|
|
1,306
|
|
Property, plant
and equipment, net
|
1,156
|
|
|
1,145
|
|
Goodwill
|
6,392
|
|
|
6,335
|
|
Intangible assets,
net
|
1,174
|
|
|
1,119
|
|
Investment in
equity method investees
|
474
|
|
|
462
|
|
Other
assets
|
128
|
|
|
136
|
|
Total
assets
|
$
|
10,695
|
|
|
$
|
10,503
|
|
|
|
|
|
Liabilities and
Stockholders' Equity
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts payable and
accrued expenses
|
$
|
976
|
|
|
$
|
1,021
|
|
Current portion of
long-term debt
|
141
|
|
|
36
|
|
Total current
liabilities
|
1,117
|
|
|
1,057
|
|
Long-term
debt
|
3,718
|
|
|
3,748
|
|
Other
liabilities
|
717
|
|
|
663
|
|
Redeemable
noncontrolling interest
|
77
|
|
|
80
|
|
Stockholders'
equity:
|
|
|
|
Quest Diagnostics
stockholders' equity:
|
|
|
|
Common stock, par
value $0.01 per share; 600 shares authorized as of both March 31,
2018 and
December 31, 2017; 217 and 216 shares
issued as of March 31, 2018 and December 31, 2017,
respectively
|
2
|
|
|
2
|
|
Additional paid-in
capital
|
2,616
|
|
|
2,612
|
|
Retained
earnings
|
7,249
|
|
|
7,138
|
|
Accumulated other
comprehensive loss
|
(41)
|
|
|
(48)
|
|
Treasury stock, at
cost; 81 shares as of both March 31, 2018 and December 31,
2017
|
(4,796)
|
|
|
(4,783)
|
|
Total Quest
Diagnostics stockholders' equity
|
5,030
|
|
|
4,921
|
|
Noncontrolling
interests
|
36
|
|
|
34
|
|
Total stockholders'
equity
|
5,066
|
|
|
4,955
|
|
Total liabilities
and stockholders' equity
|
$
|
10,695
|
|
|
$
|
10,503
|
|
Quest Diagnostics
Incorporated and Subsidiaries
|
Consolidated
Statements of Cash Flows
|
For the Three
Months Ended March 31, 2018 and 2017
|
(in
millions)
|
(unaudited)
|
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
Cash flows from
operating activities:
|
|
|
|
Net income
|
$
|
189
|
|
|
$
|
175
|
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
Depreciation and
amortization
|
74
|
|
|
62
|
|
Provision for
doubtful accounts
|
3
|
|
|
2
|
|
Deferred income tax
provision
|
24
|
|
|
11
|
|
Stock-based
compensation expense
|
19
|
|
|
17
|
|
Other, net
|
(1)
|
|
|
1
|
|
Changes in operating
assets and liabilities:
|
|
|
|
Accounts
receivable
|
(97)
|
|
|
(35)
|
|
Accounts payable and
accrued expenses
|
(68)
|
|
|
(95)
|
|
Income taxes
payable
|
5
|
|
|
63
|
|
Other assets and
liabilities, net
|
32
|
|
|
(5)
|
|
Net cash provided
by operating activities
|
180
|
|
|
196
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
Business
acquisitions, net of cash acquired
|
(130)
|
|
|
(1)
|
|
Capital
expenditures
|
(73)
|
|
|
(42)
|
|
Increase in
investments and other assets
|
(1)
|
|
|
(4)
|
|
Net cash used in
investing activities
|
(204)
|
|
|
(47)
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
Proceeds from
borrowings
|
935
|
|
|
—
|
|
Repayments of
debt
|
(832)
|
|
|
(2)
|
|
Purchases of treasury
stock
|
(50)
|
|
|
(150)
|
|
Exercise of stock
options
|
34
|
|
|
46
|
|
Employee payroll tax
withholdings on stock issued under stock-based compensation
plans
|
(20)
|
|
|
(22)
|
|
Dividends
paid
|
(61)
|
|
|
(62)
|
|
Distributions to
noncontrolling interests
|
(15)
|
|
|
(9)
|
|
Sale of
noncontrolling interest in subsidiaries
|
2
|
|
|
—
|
|
Other financing
activities, net
|
18
|
|
|
33
|
|
Net cash provided
by (used in) financing activities
|
11
|
|
|
(166)
|
|
|
|
|
|
Net change in cash
and cash equivalents and restricted cash
|
(13)
|
|
|
(17)
|
|
Cash and cash
equivalents and restricted cash, beginning of period
|
137
|
|
|
384
|
|
Cash and cash
equivalents and restricted cash, end of period
|
$
|
124
|
|
|
$
|
367
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
124
|
|
|
$
|
367
|
|
Restricted
cash
|
—
|
|
|
—
|
|
Cash and cash
equivalents and restricted cash, end of period
|
$
|
124
|
|
|
$
|
367
|
|
|
|
|
|
Cash paid during
the period for:
|
|
|
|
Interest
|
$
|
49
|
|
|
$
|
46
|
|
Income
taxes
|
$
|
2
|
|
|
$
|
8
|
|
Notes to Financial Tables
1) The
computation of basic and diluted earnings per common share is as
follows:
|
|
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
|
(in millions, except
per
share data)
|
Amounts
attributable to Quest Diagnostics' common
stockholders:
|
|
|
|
Net income
attributable to Quest Diagnostics
|
$
|
177
|
|
|
$
|
164
|
|
Less: earnings
allocated to participating securities
|
1
|
|
|
1
|
|
Earnings available to
Quest Diagnostics' common stockholders - basic and
diluted
|
$
|
176
|
|
|
$
|
163
|
|
|
|
|
|
Weighted average
common shares outstanding - basic
|
136
|
|
|
137
|
|
Effect of dilutive
securities:
|
|
|
|
Stock options and
performance share units
|
3
|
|
|
4
|
|
Weighted average
common shares outstanding - diluted
|
139
|
|
|
141
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common
stockholders:
|
|
|
|
Basic
|
$
|
1.30
|
|
|
$
|
1.19
|
|
Diluted
|
$
|
1.27
|
|
|
$
|
1.16
|
|
2) The following
tables reconcile reported GAAP results to non-GAAP adjusted
results:
|
|
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
|
(dollars in millions,
except
per share data)
|
Adjusted operating
income:
|
|
|
|
Operating
income
|
$
|
272
|
|
|
$
|
279
|
|
Restructuring and
integration charges (a)
|
31
|
|
|
18
|
|
Adjusted operating
income
|
$
|
303
|
|
|
$
|
297
|
|
|
|
|
|
Adjusted operating
income as a percentage of net revenues:
|
|
|
|
Operating income as a
percentage of net revenues
|
14.5
|
%
|
|
15.4
|
%
|
Restructuring and
integration charges (a)
|
1.6
|
|
|
0.9
|
|
Adjusted operating
income as a percentage of net revenues
|
16.1
|
%
|
|
16.3
|
%
|
|
|
|
|
Adjusted net
income:
|
|
|
|
Net income
attributable to Quest Diagnostics
|
$
|
177
|
|
|
$
|
164
|
|
Restructuring and
integration charges (a)
|
31
|
|
|
18
|
|
Income tax benefit
associated with special items (b)
|
(16)
|
|
|
(23)
|
|
Adjusted net
income
|
$
|
192
|
|
|
$
|
159
|
|
|
|
|
|
Adjusted diluted
EPS excluding amortization expense:
|
|
|
|
Diluted earnings per
common share
|
$
|
1.27
|
|
|
$
|
1.16
|
|
Restructuring and
integration charges (a) (b)
|
0.17
|
|
|
0.08
|
|
Amortization expense
(c)
|
0.14
|
|
|
0.09
|
|
ETB (d)
|
(0.06)
|
|
|
(0.11)
|
|
Adjusted diluted EPS
excluding amortization expense
|
$
|
1.52
|
|
|
$
|
1.22
|
|
|
(a) For the
three months ended March 31, 2018, represents costs primarily
associated with workforce
reductions, systems conversions and integration incurred in
connection with further restructuring
and integrating our business. For the three months ended
March 31, 2017, represents costs
primarily associated with systems conversions and integration
incurred in connection with further
restructuring and integrating our business. The following
table summarizes the pre-tax impact of
restructuring and integration charges on the company's consolidated
statements of operations:
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
|
(dollars in
millions)
|
Cost of
services
|
$
|
12
|
|
|
$
|
10
|
|
Selling, general and
administrative
|
18
|
|
|
8
|
|
Other operating
expense, net
|
1
|
|
|
—
|
|
Operating
income
|
$
|
31
|
|
|
$
|
18
|
|
|
(b) For
restructuring and integration charges, income tax impacts, where
recorded, were calculated using
combined tax rates of 25.5% and 38.7% for 2018 and 2017,
respectively. The following table
summarizes the income tax benefit associated with special
items:
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
|
(dollars in
millions)
|
Restructuring and
integration charges
|
$
|
(8)
|
|
|
$
|
(7)
|
|
ETB (d)
|
(8)
|
|
|
(16)
|
|
|
$
|
(16)
|
|
|
$
|
(23)
|
|
|
(c)
Represents the impact of amortization expense on diluted earnings
per common share, net of the income tax
benefit. The income tax benefit was primarily calculated
using combined tax rates of 25.5% and 38.7% for
2018 and 2017, respectively. The pre-tax amortization expense
that is excluded from the calculation of
adjusted diluted EPS excluding amortization expense is recorded in
the company's statements of operations
as follows:
|
|
Three Months
Ended
March 31,
|
|
2018
|
|
2017
|
|
(dollars in
millions)
|
Amortization of
intangible assets
|
$
|
22
|
|
|
$
|
17
|
|
Equity in earnings of
equity method investees, net of taxes
|
4
|
|
|
4
|
|
|
$
|
26
|
|
|
$
|
21
|
|
|
(d)
Represents the impact of ETB recorded in income tax
expense.
|
3) For the three
months ended March 31, 2018, the company repurchased 0.5
million shares of its common
stock for
$50 million. At March 31, 2018, $0.9 billion remained
available under the company's share
repurchase
authorizations.
|
|
4) The outlook
for adjusted diluted EPS excluding amortization expense represents
management's estimates
for the full
year 2018 before the impact of special items, including ETB, and
amortization expense. Further
impacts to
earnings related to special items may be incurred throughout the
remainder of the year.
Additionally, the amount of ETB is dependent upon employee stock
option exercises and the company's
stock price,
which are difficult to predict. The following table
reconciles our 2018 outlook for adjusted diluted
EPS
excluding amortization expense to the corresponding amounts
determined under GAAP:
|
|
Low
|
|
High
|
Diluted earnings per
common share
|
$
|
5.42
|
|
|
$
|
5.62
|
|
Restructuring and
integration charges (a)
|
0.59
|
|
|
0.59
|
|
Amortization expense
(b)
|
0.58
|
|
|
0.58
|
|
ETB (c)
|
(0.09)
|
|
|
(0.09)
|
|
Adjusted diluted EPS
excluding amortization expense
|
$
|
6.50
|
|
|
$
|
6.70
|
|
|
(a)
Represents estimated full year pre-tax charges of $110 million
primarily associated with systems conversions,
integration and workforce reductions incurred in connection with
further restructuring and integrating our
business. Income tax benefits were calculated using a
combined tax rate of 25.5%.
|
|
(b)
Represents the estimated impact of amortization expense for 2018 on
the calculation of adjusted diluted EPS
excluding amortization expense. Amortization expense used in
the calculation is as follows (dollars in millions):
|
Amortization of
intangible assets
|
$
|
91
|
|
Amortization expense
included in equity in earnings of equity method investees, net of
taxes
|
16
|
|
Total pre-tax
amortization expense
|
$
|
107
|
|
|
|
Total amortization
expense, net of an estimated tax benefit
|
$
|
80
|
|
|
(c)
Represents the estimated full year impact of ETB.
|
5) The outlook
for 4% to 5% revenue growth in 2018 represents management's
estimates for 2018 versus
2017
reported revenues adjusted to reflect the impact of new revenue
recognition rules that became
effective
January 1, 2018. Under the new rules, the Company will report
uncollectible balances
associated
with patient responsibility as a reduction in net revenues when
historically these amounts
were
classified as bad debt expense within selling, general and
administrative expenses.
|
|
|
|
The following tables
reconcile our 2017 net revenues determined under previous revenue
recognition rules with 2017 net revenue adjusted to reflect the
impact of the new revenue recognition rules:
|
|
Three Months
Ended
|
|
Year
Ended
|
|
March 31,
2017
|
|
June 30,
2017
|
|
September 30,
2017
|
|
December 31,
2017
|
|
December 31,
2017
|
|
(dollars in
millions)
|
2017 Revenue on an
adjusted basis:
|
|
|
|
|
|
|
|
|
Net
revenues
|
$
|
1,899
|
|
|
$
|
1,943
|
|
|
$
|
1,931
|
|
|
$
|
1,936
|
|
|
$
|
7,709
|
|
Adjustment for
adoption of new revenue
recognition rules
|
(82)
|
|
|
(79)
|
|
|
(75)
|
|
|
(71)
|
|
|
(307)
|
|
2017 Revenue on an
adjusted basis
|
$
|
1,817
|
|
|
$
|
1,864
|
|
|
$
|
1,856
|
|
|
$
|
1,865
|
|
|
$
|
7,402
|
|
|
|
|
|
|
|
|
|
|
|
2018 Revenue
outlook:
|
|
|
|
|
|
|
|
2017 Revenue on an
adjusted basis
|
|
|
|
|
|
|
$
|
7,402
|
|
|
$
|
7,402
|
|
2018 Equivalent
revenue growth
|
|
|
|
|
|
|
4
|
%
|
|
5
|
%
|
2018 Revenue
outlook
|
|
|
|
|
|
|
$
|
7,698
|
|
|
$
|
7,772
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-reports-first-quarter-2018-financial-results-300632579.html
SOURCE Quest Diagnostics